PERTH, Australia – Starpharma Holdings Ltd. is pausing sales of its antiviral nasal spray, Viraleze (SPL-7013), in the U.K. after its retail partner, Lloydspharmacy, received a letter from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) related to promotional claims made about the antiviral with respect to SARS-CoV-2 and COVID-19.
LONDON – New data from a randomized community study involving more than half a million people has shown that of 92,116 who had symptomatic COVID-19, 38% were still reporting symptoms 12 weeks later.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: BD, Cardiofocus, Flo Health, Hologic, Innova, Integrity Implants, New View Surgical, Penumbra.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Corelink, Fist Assist Devices, Onkos Surgical, Phase Scientific.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aidoc, Aptar, Avania, Garwood, Icometrix, Imarc, Integrum, Mirador, Prognos, Sorrento Therapeutics, Thermo Fisher Scientific, Voluntis.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aiforia, Alibaba Health, Anatech, Avacta Group, Berry Oncology, Calibre Scientific, Cancer Diagnostics, Efferent Health, Epredia, Madison Core Laboratories, Paige, Parvizi Surgical Innovation, Predictive Health Diagnostics Company, Raysearch, SHL Telemedicine, VNA Care.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Co-Diagnostics, Hecin, Holista Colltech.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Boston Scientific, Edevice, Genesis Medtech Group, Horcon, Inivata, Neogenomics, Pattern Computer, Predictmedix, Rakuten Medical, Shimadzu.
About a year-and-a-half after the sequencing of the SARS-CoV-2 virus and the onslaught of COVID-19 therapeutic and vaccine development that followed, the biopharma industry boldly tackles a slew of ongoing issues from vaccine hesitancy and supply inequities to the ramifications of a potential intellectual property waiver and the pressing need to prepare global systems for the next pandemic.
